title: The differences in RCAS1 and DFF45 endometrial expression between late proliferative, early secretory, and mid-secretory cycle phases.
abstract: RCAS1 expression is related to the regulation of activated immune cells and to connective tissue remodeling within the endometrium. DFF45 seems to play an important role in the apoptotic process, most likely by acting through the regulation of DNA fragmentation. Its expression changes within the endometrium seem to be related to the resistance of endometrial cells to apoptosis. The aim of the present study was to evaluate RCAS1 and DFF45 endometrial expressions during ovulation and the implantation period. RCAS1 and DFF45 expression was assessed by the Western-blot method in endometrial tissue samples obtained from 20 patients. The tissue samples were classified according to the menstrual cycle phases in which they were collected, with a division into three phases: late proliferative, early secretory, and mid-secretory. The lowest level of RCAS1 and the highest level of DFF45 endometrial expression was found during the early secretory cycle phase. Statistically significantly higher RCAS1 and statistically significantly lower DFF45 endometrial expression was identified in the endometrium during the late proliferative as compared to the early secretory cycle phase. Moreover, statistically significantly higher RCAS1 and statistically significantly lower DFF45 expression was found in the endometrium during the mid-secretory as compared to the early secretory cycle phase. The preparation for implantation process in the endometrium is preceded by dynamic changes in endometrial ECM and results from the proper interaction between endometrial and immune cells. The course of this process is conditioned by the immunomodulating activity of endometrial cells and their resistance to immune-mediated apoptosis. These dynamic changes are closely related to RCAS1 and DFF45 expression alterations.
authors.affiliation: Department of Gynecology, Obstetrics and Oncology of the Jagiellonian University, Kraków, Poland.
authors.forename: Tadeusz J
authors.initials: TJ
authors.lastname: Popiela
authors.forename: Lukasz
authors.initials: L
authors.lastname: Wicherek
authors.forename: Michal
authors.initials: M
authors.lastname: Radwan
authors.forename: Jerzy
authors.initials: J
authors.lastname: Sikora
authors.forename: Tomasz
authors.initials: T
authors.lastname: Banas
authors.forename: Pawel
authors.initials: P
authors.lastname: Basta
authors.forename: Magdalena
authors.initials: M
authors.lastname: Kulczycka
authors.forename: Marek
authors.initials: M
authors.lastname: Grabiec
authors.forename: Bogdan
authors.initials: B
authors.lastname: Obrzut
authors.forename: Jaroslaw
authors.initials: J
authors.lastname: Kalinka
mesh_terms: D000328:Adult; D000951:Antigens, Neoplasm / Q000096:biosynthesis*; D017209:Apoptosis / Q000276:immunology; D051017:Apoptosis Regulatory Proteins / Q000096:biosynthesis*; D015153:Blotting, Western; D010064:Embryo Implantation / Q000276:immunology; D004717:Endometrium / Q000276:immunology / Q000378:metabolism*; D005260:Female; D006801:Humans; D007090:Image Interpretation, Computer-Assisted; D008597:Menstrual Cycle / Q000276:immunology / Q000502:physiology*; D008875:Middle Aged; D010062:Ovulation Induction / Q000379:methods
chemical_list: D000951:Antigens, Neoplasm; D051017:Apoptosis Regulatory Proteins; C120762:EBAG9 protein, human; C109664:caspase-activated DNase inhibitor